Open for inclusion

A douple blind, randomized , two-arm phase 2 study of nivolumab in combination with ipilimumab versus nivolumab in cimbination with ipilimumab placebo in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Cancer type: Head and Neck cancer

Phase: II

Principal Investigator: Hernberg Micaela

Country: FI

Keywords: Finland, Helsinki,nivolumab, ipilimumab

Status: Open for inclusion

Link to